HUTCHMED (HCMN) AI Stock Analysis

HUTCHMED

(BMV:HCMN)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Conservative Balance SheetVery low leverage gives HUTCHMED financial flexibility to fund research, development and commercialization without substantial debt servicing pressure. A solid equity base also improves resilience if operating losses persist or pipeline investment needs remain elevated over the next several quarters.

Negative Factors

Negative Core ProfitabilityPersistently negative operating margins show that the core business is not yet converting revenue into sustainable operating profit. This can limit internally funded growth, increase dependence on product uptake or partners, and make future earnings more sensitive to development and commercialization spending.

HUTCHMED Business Overview & Revenue Model

Company Description

HUTCHMED (China) Limited is a biopharmaceutical firm dedicated to the discovery, advancement, and marketing of innovative targeted and immune-based treatments for various cancers and immune-related disorders. Its operations are divided into two main...

HUTCHMED Risk Analysis

HUTCHMED disclosed 90 risk factors in its most recent earnings report. HUTCHMED reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks

1.We are a Cayman Islands company. As judicial precedent regarding the rights of shareholders is more limited under Cayman Islands law than under U.S. law or English law, shareholders may have different shareholder rights than they would have under U.S. law or English law and may face difficulties in protecting your interests.Q4, 2019

2.We are subject to liquidity risk with respect to our investments in our joint ventures.Q4, 2019

3.Although we have obtained orphan drug designation for surufatinib for the treatment of pancreatic neuroendocrine tumors in the United States, we may not be able to obtain or maintain the benefits associated with orphan drug status, including market exclusivity.Q4, 2019

HUTCHMED Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

MX:HCMN against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RDY	67Neutral	$11.86B	40.24	7.37%	0.59%	-10.52%	-55.45%
TAK	67Neutral	$67.25B	27.16	5.07%	3.37%	0.67%	-12.01%
TEVA	65Neutral	$47.43B	70.17	9.18%	―	4.40%	―
AMRX	59Neutral	$7.49B	43.24	-326.75%	―	9.28%	4917.17%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALKS	47Neutral	$7.61B	112.51	3.72%	―	10.79%	-81.14%

* Healthcare Sector Average

Performance Comparison

MX:HCMN and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
ALKS	Alkermes plc	45.34	15.17	50.28%
RDY	Dr. Reddy's Laboratories Ltd	14.17	0.83	6.25%
TEVA	Teva Pharmaceutical Industries Limited	42.09	23.59	127.51%
AMRX	Amneal Pharma	21.51	10.32	92.14%
TAK	Takeda Pharmaceutical Company	20.91	7.49	55.81%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

HUTCHMED AI Stock Analysis